Literature DB >> 12573435

The core-binding factor leukemias: lessons learned from murine models.

James R Downing1.   

Abstract

The recent development of murine models of core-binding factor leukemias has provided important insights into the underlying molecular pathology of this common subtype of acute myeloid leukemia. Evidence from these models supports the idea that acute myeloid leukemia 1/core-binding factor beta-subunit (AML1/CBFbeta) has a critical role in the control of the self-renewal capacity of hematopoietic stem cells and their progeny. Moreover, the accumulated data demonstrate that the expression of translocation-encoded AML1 or CBFbeta fusion proteins are insufficient by themselves to induce a full leukemic phenotype. The models that have been developed should prove to be of value for defining the range of mutations that can cooperate with AML1/CBFbeta fusion proteins, and for assessing novel therapies targeted toward the pathways that are altered by the expression of these fusion proteins.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12573435     DOI: 10.1016/s0959-437x(02)00018-7

Source DB:  PubMed          Journal:  Curr Opin Genet Dev        ISSN: 0959-437X            Impact factor:   5.578


  21 in total

1.  Folylpolyglutamate synthetase gene transcription is regulated by a multiprotein complex that binds the TEL-AML1 fusion in acute lymphoblastic leukemia.

Authors:  Guy J Leclerc; Christopher Sanderson; Stephen Hunger; Meenakshi Devidas; Julio C Barredo
Journal:  Leuk Res       Date:  2010-06-09       Impact factor: 3.156

2.  Distinct classes of c-Kit-activating mutations differ in their ability to promote RUNX1-ETO-associated acute myeloid leukemia.

Authors:  Heidi J Nick; Hyung-Gyoon Kim; Chia-Wei Chang; Kevin W Harris; Vishnu Reddy; Christopher A Klug
Journal:  Blood       Date:  2011-09-21       Impact factor: 22.113

Review 3.  Core binding factor acute myeloid leukemia: Advances in the heterogeneity of KIT, FLT3, and RAS mutations (Review).

Authors:  Xi Quan; Jianchuan Deng
Journal:  Mol Clin Oncol       Date:  2020-05-25

4.  Core-binding factor acute myeloid leukemia in pediatric patients enrolled in the AIEOP AML 2002/01 trial: screening and prognostic impact of c-KIT mutations.

Authors:  E Manara; V Bisio; R Masetti; V Beqiri; R Rondelli; G Menna; C Micalizzi; N Santoro; F Locatelli; G Basso; M Pigazzi
Journal:  Leukemia       Date:  2013-11-14       Impact factor: 11.528

Review 5.  FLT3 inhibitors in the treatment of acute myeloid leukemia: the start of an era?

Authors:  Naveen Pemmaraju; Hagop Kantarjian; Farhad Ravandi; Jorge Cortes
Journal:  Cancer       Date:  2011-02-11       Impact factor: 6.860

Review 6.  The genomics of acute myeloid leukemia in children.

Authors:  Shannon E Conneely; Rachel E Rau
Journal:  Cancer Metastasis Rev       Date:  2020-03       Impact factor: 9.264

7.  Comprehensive mutational profiling of core binding factor acute myeloid leukemia.

Authors:  Nicolas Duployez; Alice Marceau-Renaut; Nicolas Boissel; Arnaud Petit; Maxime Bucci; Sandrine Geffroy; Hélène Lapillonne; Aline Renneville; Christine Ragu; Martin Figeac; Karine Celli-Lebras; Catherine Lacombe; Jean-Baptiste Micol; Omar Abdel-Wahab; Pascale Cornillet; Norbert Ifrah; Hervé Dombret; Guy Leverger; Eric Jourdan; Claude Preudhomme
Journal:  Blood       Date:  2016-03-15       Impact factor: 22.113

Review 8.  Steroid resistance in leukemia.

Authors:  Darshan S Shah; Raj Kumar
Journal:  World J Exp Med       Date:  2013-05-20

9.  AML1/Runx1 is important for the development of hindbrain cholinergic branchiovisceral motor neurons and selected cranial sensory neurons.

Authors:  Francesca M Theriault; Priscillia Roy; Stefano Stifani
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-06       Impact factor: 11.205

10.  FLT3-ITD cooperates with inv(16) to promote progression to acute myeloid leukemia.

Authors:  Hyung-Gyoon Kim; Kyoko Kojima; C Scott Swindle; Claudiu V Cotta; Yongliang Huo; Vishnu Reddy; Christopher A Klug
Journal:  Blood       Date:  2007-10-29       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.